Nasopharyngeal Carcinoma - 31 Studies Found
| RECRUITING |
: Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma : Nasopharyngeal Carcinoma : 2024-11-24 : Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy. |